THE DISCOVERY AND DEVELOPMENT OF ZILEUTON - AN ORALLY ACTIVE 5-LIPOXYGENASE INHIBITOR

被引:99
|
作者
BELL, RL
YOUNG, PR
ALBERT, D
LANNI, C
SUMMERS, JB
BROOKS, DW
RUBIN, P
CARTER, GW
机构
[1] Immunoscience Research Area and Immunoscience Venture, Abbott Laboratories, Abbott Park
来源
INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY | 1992年 / 14卷 / 03期
关键词
D O I
10.1016/0192-0561(92)90182-K
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The enzyme 5-lipoxygenase is a key target in the effort to discover drugs which inhibit the pathophysiology associated with the formation of leukotrienes. The research efforts of these laboratories have focused on the discovery of direct enzyme inhibitors of 5-lipoxygenase. In particular, compounds with hydroxamate or N-hydroxyurea functionalities have proven to be potent inhibitors of leukotriene biosynthesis in vitro and more importantly in vivo. One of these compounds, zileuton (N-(1-benzo-[b]-thien-2-ylethyl)-N-hydroxyurea) has been shown recently to be an effective leukotriene inhibitor in man. The critical approaches and breakthroughs in the discovery and development of zileuton are described. In addition, some recent results with zileuton in animals and man are detailed.
引用
收藏
页码:505 / 510
页数:6
相关论文
共 50 条
  • [1] DISCOVERY AND SYNTHESIS OF SB-202235, AN ORALLY ACTIVE INHIBITOR OF 5-LIPOXYGENASE
    ADAMS, JL
    GARIGIPATI, RS
    SORENSON, M
    ROSS, S
    SCHMIDT, SJ
    GLEASON, JG
    GRISWOLD, DE
    WEBB, EF
    BRETON, JJ
    MARSHALL, P
    HAY, D
    UNDERWOOD, D
    TORPHY, T
    NEWTON, JF
    TYRRELL, KA
    GARVER, E
    YODIS, L
    BRIAN, WR
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1992, 204 : 21 - MEDI
  • [2] ZILEUTON - A 5-LIPOXYGENASE INHIBITOR IN RHEUMATOID-ARTHRITIS
    WEINBLATT, ME
    KREMER, JM
    COBLYN, JS
    HELFGOTT, S
    MAIER, AL
    PETRILLO, G
    HENSON, B
    RUBIN, P
    SPERLING, R
    JOURNAL OF RHEUMATOLOGY, 1992, 19 (10) : 1537 - 1541
  • [4] CGS 22745 - A SELECTIVE ORALLY ACTIVE INHIBITOR OF 5-LIPOXYGENASE
    KIMBLE, E
    KOWALSKI, T
    WHITE, D
    RAYCHAUDURI, A
    PASTOR, G
    CHERTOCK, H
    LEE, W
    NEALE, R
    HAMDAN, A
    WASLEY, J
    AGENTS AND ACTIONS, 1991, 34 (1-2): : 125 - 128
  • [5] Zileuton: The first 5-lipoxygenase inhibitor for the treatment of asthma
    Wenzel, SE
    Kamada, AK
    ANNALS OF PHARMACOTHERAPY, 1996, 30 (7-8) : 858 - 864
  • [6] SYNTHESIS OF THE 5-LIPOXYGENASE INHIBITOR ZILEUTON FROM THIOPHENOL
    BASHA, A
    BROOKS, DW
    JOURNAL OF ORGANIC CHEMISTRY, 1993, 58 (05): : 1293 - 1294
  • [7] Development of CMI-977 as a potent and orally active 5-lipoxygenase inhibitor.
    Cai, X
    Cheah, S
    Chen, SM
    Eckman, J
    Ellis, J
    Fisher, R
    Fura, A
    Grewal, G
    Hussion, S
    Ip, S
    Killian, DB
    LibertineGarahan, L
    Lounsbury, H
    Qian, CG
    Scannell, RT
    Yaeger, D
    Wypij, DM
    Yeh, CG
    Young, MA
    Yu, SX
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1997, 214 : 214 - MEDI
  • [8] KINETICS AND MECHANISM OF DEGRADATION OF ZILEUTON, A POTENT 5-LIPOXYGENASE INHIBITOR
    ALVAREZ, FJ
    SLADE, RT
    PHARMACEUTICAL RESEARCH, 1992, 9 (11) : 1465 - 1473
  • [9] R-85355 - A POTENT, ORALLY ACTIVE 5-LIPOXYGENASE INHIBITOR
    BEETENS, JR
    BEERENS, D
    VANAMMEL, K
    SOMERS, Y
    LOOTS, W
    DECLERCK, F
    PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY, 1991, 419 (01): : R3 - R3
  • [10] A-64077, A NEW POTENT ORALLY ACTIVE 5-LIPOXYGENASE INHIBITOR
    CARTER, GW
    YOUNG, PR
    ALBERT, DH
    BOUSKA, JB
    DYER, RD
    BELL, RL
    SUMMERS, JB
    BROOKS, DW
    GUNN, BP
    RUBIN, P
    KESTERSON, J
    LEUKOTRIENES AND PROSTANOIDS IN HEALTH AND DISEASE, 1989, 3 : 50 - 55